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Abstract 
Background: Human mesenchymal stem cells (MSC), during in vitro expansion, undergo a progressive loss of prolif-
erative potential that leads to the senescent state, associated with a reduction of their “medicinal” properties. This may 
hampers their efficacy in the treatment of injured tissues. Quality controls on MSC-based cell therapy products should 
include an assessment of the senescent state. However, a reliable and specific marker is still missing. From stud-
ies on lamin-associated disorders, has emerged the correlation between defective lamin A maturation and cellular 
senescence.
Findings: Primary cultured hMSC lines (n = 3), were analyzed by immunostaining at different life-span stages for the 
accumulation of prelamin A, along with other markers of cellular senescence. During culture, cells at the last stage 
of their life span displayed evident signs of senescence consistent with the positivity of SA-β-gal staining. We also 
observed a significant increase of prelamin A positive cells. Furthermore, we verified that the cells marked by prelamin 
A were also positive for p21Waf1 while negative for Ki67.
Conclusions: Overall data support that the detection of prelamin A identifies senescent MSC, providing an easy and 
reliable tool to be use alone or in combination with known senescence markers to screen MSC before their use in 
clinical applications.
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Background
Human mesenchymal stem cells (MSC) have raised 
high hopes in various therapeutic applications and their 
use is currently tested in about 500 clinical trials (www.
clinicaltrials.gov). For many clinical approaches these 
cells are usually expanded in vitro prior to their utiliza-
tion. However, MSC can undergo only a limited number 
of cell divisions under standard culture conditions, and it 
has been demonstrated that during in vitro proliferation 
they suffer a progressive and continuous process of aging 
(Wagner et  al. 2008) that affects the proliferation and 
multilineage differentiation potential (Banfi et  al. 2000; 
Kim et  al. 2010), the immunomodulatory properties 
(Sepúlveda et al. 2014), the secretory profile (Coppe et al. 
2010), the gene expression profile, and the epigenetic sig-
nature (Schellenberg et  al. 2011; Yoo et  al. 2013). These 
changes may impact the efficacy of MSC to treat injured 
tissues. For this reason, it is generally recommended in 
clinical applications to use MSC that have been cultured 
only for a restricted amount of time, fixing a threshold 
that limits their number of passages or population dou-
blings (de Girolamo et al. 2013; Wuchter et al. 2014).
Cellular senescence is a complex process, which mani-
fests with different, multifaceted phenotypes depending 
on the species, the cell type, and the senescence-inducing 
stimulus (Kosar et al. 2011). This lack of a unique signa-
ture implies the necessity for a mindful selection of the 
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proper marker or panel of markers when assessing the 
senescence status of in  vitro cultured MSC. The detec-
tion of SA-β-gal activity is the most common assay for 
the evaluation of cell senescence due to the availability 
of well-established protocols and commercial kits, and 
the abundant bibliography reporting its use. However 
the limitations of this marker are universally recognized 
(Crowe et al. 2014; Debacq-Chainiaux et al. 2008; Wag-
ner et  al. 2009). Other markers of senescence, oppor-
tunely reviewed by de Jesus (de Jesus and Blasco 2012), 
such as telomere shortening, Senescence-Associated 
Heterochromatin Foci (SAHF), Promyelocytic Leuke-
mia Protein Nuclear Bodies, and Senescence-associated 
secretory phenotype (SASP) have been proposed over 
years. Recently, new approaches specifically focused on 
MSC have been suggested. Shibata et  al. explored the 
expression of the p16INK4A gene, suggesting its methyla-
tion state could be monitored as a surveillance against 
the transformation of MSC during culture (Shibata et al. 
2007). Koch et al. proposed instead the use of the DNA-
methylation changes observed at specific CpG sites in 
MSC and fibroblast to track the state of cellular senes-
cence (Koch et al. 2012).
We moved from the observation of the phenomena 
that influence or lead to aging in humans, in order to 
identify a reliable and specific marker of the senescence 
phenotype of MSC.
In this regard, alteration of the nuclear lamina is known 
as one of the cellular changes observed in physiological 
aging (Vlcek and Foisner 2007; Lattanzi et  al. 2014). Of 
particular interest is the LMNA gene that encodes two 
components of the nuclear envelope: lamin A and C. 
The maturation of lamin A is an elaborate process which 
involves  several consecutive steps including: farnesyla-
tion, the proteolytic cleavage of three N-terminal amino 
acids, the carboxymethylation and the  final removal of 
additional fifteen N-terminal amino acids including the 
farnesyl group. The final step is exclusively catalyzed 
by the zinc-metallopeptidase ZMPSTE24 encoded by 
the FACE-1 gene. Mutations affecting different steps or 
actors of the maturation process, which elicits the accu-
mulation of wild-type or mutated prelamin A, are asso-
ciated with progeroid laminopathies or lipodystrophy 
(Broers and Ramaekers 2006; Davies et  al. 2011). These 
diseases, including the Hutchinson-Gilford progeria syn-
drome that is characterized by premature aging, mainly 
affect tissues of mesenchymal origin, suggesting a link 
between prelamin A and MSC senescence.
The existence of this correlation was supported by the 
work of Scaffidi and Misteli. Their results demonstrated 
that the accumulation of wild type or mutant lamin A by 
means of expression vectors or drugs leads to an accel-
erated aging of human fibroblast and immortalized 
MSC (Scaffidi and Misteli 2008). Our goal was to ver-
ify this correlation the other way around, and so where 
replicative senescence of primary MSC culture leads to 
prelamin A accumulation. The presence of lamin A pre-
cursors in cells after their prolonged in vitro culture or in 
tissue specimens from aged donors was already observed 
by other investigators, but their analysis was focused on 
Vascular Smooth Muscle Cells (Ragnauth et al. 2010).
As far as we know, a general and robust detection 
analysis of lamin A precursor in MSC that have naturally 
exited the replicative cycle in normal culture conditions 
has never been reported. Therefore, in our work we used 
primary cultures of human MSC isolated from the bone 
marrow of healthy donors to investigate the presence 
of unprocessed lamin A precursor during early and late 
stages of in vitro cultures, with the ultimate scope of pro-
posing a proper marker to detect senescent MSC.
Methods
Primary human MSC were obtained from 3 non-onco-
logic patients (aged 20, 26, 6) during routine orthopedic 
surgical procedures.
Cell isolation and expansion is described in the Addi-
tional file.
Definition of early and late stages of in vitro MSC culture
MSC were maintained in culture until they reached their 
maximal life span as evidenced by growth arrest (i.e. 
the cells failed to become confluent within 4  weeks of 
culture).
The number of population doublings (PD) for each pas-
sage was calculated using the formula: log2(N1/N0), where 
N0 is the number of cells seeded and N1 is the number 
of cells harvested at the end of the passage. Cumulative 
population doublings (CPD) were calculated as the sum 
of PDs over passages.
CPD curves were normalized with GraphPad Prism 6 
Software to set the maximum CPD value as the 100 % of 
the cell line life-span. Early and late life-span stages were 
then identified by graphical interception on the CPD 
curve tracing horizontal lines at y coordinates equal to 50 
and 80 % (Stenderup et al. 2003). Experimental observa-
tions were performed on cell samples at passages com-
prised in the “early stage” (life-span <50 %) or “late stage” 
(life-span >80 %).
Senescence associated β‑galactosidase assay
SA-β-gal activity was detected with a senescent cell stain-
ing kit (Sigma Aldrich, St. Louis, MO, USA) according 
to the manufacturer’s instructions. Briefly, the 40  mg/
ml stock solution of 5-bromo-4-chloro-3-indolyl β-d-
galactopyranoside (X-gal) was prepared in the laboratory 
by dissolving the X-gal powder (Sigma Aldrich, USA) in 
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N,N-dimethylformamide. Once prepared, it was stored at 
−20 °C and used within a month, to ensure the accuracy 
of the assay.
Cells were seeded in a 24-well plate and cultivated until 
60 % confluence. Plates were washed with PBS, fixed for 
5 min at room temperature, and incubated at 37 °C over-
night in a dry incubator with freshly prepared 1  mg/
ml X-gal buffered solution. Cell nuclei were counter-
stained with 5 µg/ml Hoechst 33342 (Life Technologies, 
Eugene, OR, USA). Microphotographs of a minimum of 
six random fields for each sample were taken using an 
epifluorescence microscope (Nikon Eclipse TE2000-U, 
Amsterdam, Netherland) equipped with a Nikon DS-Vi1-
U3 CCD color digital camera. Brightfield and fluores-
cent images were merged with NIS-D software (Nikon, 
Amsterdam, Netherlands) to count total and β-gal posi-
tive cells.
Prelamin A detection and immunostaining
MSC grown on coverslips were fixed in cold methanol 
at −20  °C for 7  min. Samples were incubated with PBS 
containing 4 % BSA to saturate non-specific binding and 
incubated overnight at 4  °C with anti-prelamin A anti-
body (Santa Cruz Sc-6214) diluted at 1:100. Coverslips 
were then washed several times in PBS and incubated 1 h 
at RT with donkey anti-goat secondary antibody (Santa 
Cruz Sc-3853) diluted 1:100. After washes with PBS, the 
nuclei were counterstained with 4,6-diamino-2-phenylin-
dole (DAPI). The slides were mounted with an anti-fade 
reagent in glycerol and observed. To measure the per-
centage of prelamin A positive cells, microphotographs of 
a minimum of 6 random fields were taken for each sam-
ple and prelamin A positive cells were manually counted. 
Imaging was performed using a laser-scanning motorized 
confocal system (Nikon A1R, Nikon, Amsterdam, Neth-
erlands) equipped with an Eclipse Ti-E inverted micro-
scope and four laser lines (405, 488, 561, and 638 nm). A 
Plan Apo VC 60x/1.4NA Oil DIC N2 objective lens was 
used. Images were processed using NIS-Elements AR 
4.10.01 software (Nikon, Amsterdam, Netherlands).
As a positive control, accumulation of prelamin A 
was obtained using 25  μM mevinolin (M2147, Sigma) 
in complete growth medium for 18  h. Mevinolin is an 
isoprenoid synthesis inhibitor that causes inhibition 
of hydroxymethyl-glutaryl-synthase implicated in the 
farnesyl pathway. This compound elicits an accumula-
tion of non-farnesylated (unprocessed) prelamin A, as 
reported in several studies (Mattioli et al. 2008).
To observe prelamin A nuclear distribution, confocal 
imaging was performed using the 488 nm laser line, and 
laser power was adjusted to minimize photobleaching. A 
Plan Apo 100x/1.4NA Oil DIC H objective lens was used. 
Zoom and field-of-view dimensions were adjusted to give 
a resolution of 1024 × 1024. Z-slices were acquired every 
0.175  μm for a total of 31 steps. NIS elements software 
permits 3D rendering of the Z-slices.
Two double immunostainings of prelamin A with p21 
or Ki67 were performed. The rabbit polyclonal anti-Ki67 
antibody (Santa Cruz Sc-15402) was diluted 1:100 and 
incubated overnight at 4  °C while the rabbit monoclo-
nal anti-p21antibody [Pierce p21 Waf1/Cip1 Antibody 
(R.229.6)] was diluted 1:300 and incubated overnight at 
4  °C. Immunofluorescence microscopy was performed 
using a Nikon E600 epifluorescence microscope and a 
Nikon oil-immersion objective [100× magnification, 1,3 
NA (numerical aperture)]. Photographs were taken using 
a Nikon digital camera (DXm) and NIS-Element AR 
software.
Results and discussion
In the production of MSC-based cell therapy prod-
ucts, safety and potency evaluations are mandatory, 
and among other aspects, the senescent state of culture 
should be assessed.
Though alternatives to the classical SA-β-gal staining 
have been proposed (Shibata et  al. 2007; Righolt et  al. 
2011; Koch et al. 2012) we believe an optimal marker for 
the identification of senescent MSC is not yet available. 
A correlation between accumulation of prelamin A and 
cellular aging has been already postulated (Scaffidi and 
Misteli 2008; Yu and Kang 2013; Yu et  al. 2013). How-
ever, the main findings of the previous studies were 
mainly obtained through an induced accumulation of 
prelamin A with expression vectors or drugs. Our goal 
was to demonstrate that the spontaneous accumulation 
of prelamin A occurs in human MSC under a condi-
tion of replicative senescence induced by the prolonged 
in vitro culture.
MSC samples were isolated from the bone marrow of 
three healthy donors and maintained under standard cul-
ture condition until they reached replicative senescence 
in culture. As expected, when expanded in vitro each of 
them presented a distinctive growth curve and progres-
sion toward the Hayflick limit (Shay and Wright 2000) 
(Fig. 1a). Even if cells are isolated and cultured under the 
same conditions, the number of passages is evidently an 
unreliable indicator of cellular aging. Observations were 
therefore planned after the analysis of the growth curves 
of each cell line both at early and late stages (Fig.  1b), 
as described in the Materials and Methods section. The 
comparison of cells belonging to the same life-span stage 
attenuates the inter-donor variability and allows the 
observation of a coherent range of modifications such as 
a gradual change from a fibroblastic-like spindle shape to 
a large widespread morphology (Fig.  1c) and a reduced 
proliferation potential in the late stage (Fig.  1d). These 
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morphological changes are associated with cytoskeleton 
alteration. In fact, β-tubulin and Vimentin immunostain-
ing analyses (Additional file  1: Fig. S1A, B), performed 
at early and late stages demonstrated the altered polari-
zation and disruption of cytoskeletal microtubules fila-
ments of senescent cells (Geißler et al. 2012).
The senescent status of the cell cultures at late stages 
was confirmed by the SA-β-gal assay that revealed an 
increased activity of the lysosomal β-D-galactosidase at 
the suboptimal pH of 6.0, compared to the cells at early 
stage (Fig.  2a). Similarly, the specific immunostain-
ing for the full-length form of lamin A precursor (with 
an antibody directed to the C-terminal residue of the 
unprocessed protein) showed a higher number of cells 
positive for prelamin A at late stages (Fig. 2b). Confocal 
microscopy performed at high magnification confirmed 
a nucleoplasmic and rim localization of prelamin A 
together with an abnormal nuclear morphology (Fig. 2c, 
c’). From the single z-stacks representative of different 
planes along the nucleus (Fig. 2c’), multiple invaginations 
of the nuclear membrane are evident. Interestingly, the 
observation of an increased incidence of wrinkled nuclei 
in senescent cells was exploited by Righolt et al. to elabo-
rate an imaging method that quantifies the intensity and 
curvature of the nuclear lamina to identify abnormal cells 
during aging, in vitro proliferation, and in lamina disor-
ders (Righolt et al. 2011).
The manual count of the percentage of SA-β-gal or 
prelamin A positive cells over the total performed on the 
3 MSC lines confirmed the qualitative results. The per-
centage of prelamin A-positive cells increases dramati-
cally from early to late stages (from 6 to 59  %), with a 
trend similar to the one observed for the SA-β-gal stain-
ing (Fig.  2d). Though the trends were similar we can 
observe that the results from prelamin A staining indi-
cate a slightly higher percentage of positive cells than 
for SA-β-gal assay both at early and late stage. The num-
ber of observations is insufficient to operate a statistical 
comparison, but the observed difference could indicate 
that the accumulation of prelamin A is a more sensitive 
marker to reveal senescent cells even at earlier stages. 
The detection of prelamin A positive cells at early stage 
is not entirely unexpected, as primary MSC culture are 
known to be composed by an heterogeneous population 
that might harbor among the active proliferating cells, 
resting, terminally differentiated or senescent cells (Sher-
ley 2002; Whitfield et al. 2013).
In addition, the variability among MSC lines observed 
for SA-β-gal counting despite we performed our analy-
ses at stages selected to reduce the inter-donor variability 
Fig. 1 MSC undergo replicative senescence during in vitro expansion. a Cumulative population doublings (CPD) of cell cultures from three differ-
ent donors. b Passages and PDT intervals corresponding to the early and late stages of each MSC cell line. The end of the late stage matches with 
replicative senescence of the culture. c Representative brightfield images of MSC at early and late stages. White boxes indicate areas of magnification 
highlighting the altered shape of senescent cells compared to the well defined spindle-shape of MSC at early stages. Scale bar 200 µm. d Doubling 
times (DT) calculated from proliferation assay confirm the remarked reduction of proliferation potential of cells according to the progression of life-
span stages
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(Fig. 1), is reduced in the prelamin A scoring, making the 
latest a more steady marker.
The discordant results from the two markers might 
also be a consequence of the limitations and techni-
cal pitfalls inherent to the SA-β-gal assay caused by the 
limited specificity and instability of β-gal substrate, as 
already outlined by other investigators (Yang and Hu 
2005; Lee et al. 2006; Debacq-Chainiaux et al. 2009). In 
this regard, the assessment of prelamin A accumula-
tion can be performed with an easy available positive 
control, in order to check the technical quality of the 
immunostaining. The positive control for prelamin A 
consists in cells treated with mevinolin, a drug known 
to inhibit farnesyl production and to cause accumula-
tion of unprocessed prelamin A (Lattanzi et  al. 2014) 
(Additional file  1: Fig.  S2). As expected from previous 
studies (Caron et  al. 2007), treatment with mevinolin 
did not induce SA-β-gal expression (Additional file  1: 
Fig. S2). This is in agreement with our data showing that 
cells from centenarian individuals spontaneously accu-
mulate prelamin A and display a more efficient response 
to oxidative stress-induced DNA damage (Lattanzi et al. 
Fig. 2 MSC under replicative senescence accumulate prelamin A. a Representative microphotograph of SA-β-gal assay performed on early and 
late stage cells. Blue staining indicates the presence of β-galactosidase activity in senescent cells. Scale bar 200 μm. b Cells at early and late stages 
were fixed and immunostained with a specific antibody against prelamin A and counterstained with DAPI. Scale bar 50 µm. c 3D digital rendering of 
Z-slices confocal images of a representative prelamin A positive cell at late stage. c’ Single slice images of different Z-stacks illustrating the distribu-
tion of prelamin A, from surface (left panel) and from middle plane (right panel) point of views. Scale bar 10 µm. d Quantification of β-gal positive 
and prelamin A positive cells at early and late stages. Blue stained cells and Hoechst stained nuclei were counted in a minimum of six random fields 
to report the percentage β-gal positive cells at early and late stages. To count prelamin A positive and total cell numbers a minimum of six random 
fields was checked at early and late stages. Data are expressed as percentage of positive cells respect to the total cell count
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2014). These data support the view that prelamin A 
accumulation does not induce senescence per se, but it 
is triggered in response to stress stimuli in the attempt to 
counteract geroconversion. In particular, we observed in 
human fibroblast that the oxidative and replicative stress 
affect prelamin A processing, through the reduction of 
ZMPSTE24 expression (Lattanzi et al. 2014) and it could 
be speculated that a similar mechanism is involved in 
prelamin A accumulation observed in senescent MSC.
Biochemical evaluation of prelamin A was also per-
formed by Western blotting analysis. Prelamin A, in 
accordance with results obtained by prelamin A immu-
nofluorescence staining, is detectable at the predicted 
molecular weight in both senescent and mevinolin-
treated MSCs (Additional file 1: Fig. S3).
We further checked the expression of p21Waf1 (Cdkn1n 
gene), a nuclear protein that indicates senescence-asso-
ciated cell-cycle arrest (Kong et  al. 2011), and Ki67, a 
marker of proliferating cells expressed in all active phases 
of the cell cycle (G1, S, G2). As hypothesized, cells posi-
tive for prelamin A showed p21Waf1 staining in nuclei and 
were negative for Ki67 (Fig. 3), confirming that prelamin 
A-labeled MSC underwent replicative senescence during 
in vitro culture.
Based on our observations, the nuclear accumulation 
of prelamin A identifies senescent cells in human MSC 
cultures.
It is worth noting that previous reports indicate that 
the accumulation of mutated forms or precursors of 
lamin A triggers a series of molecular changes that 
diminish the specific properties of the MSC such as the 
multilineage differentiation potential (Yu et  al. 2013; 
Malashicheva et  al. 2015) and the capacity to promote 
the repair of injured tissues (Infante et al. 2014). There-
fore, prelamin A accumulation can be therefore consid-
ered a candidate marker for the detection of senescent 
cells during MSC expansion and can be exploited to dis-
card aged cells, characterized by low differentiation and 
regeneration capacity, and thus prevent their release for 
clinical purposes.
Conclusions
Despite the underlying molecular mechanisms are still 
unraveled, replicative senescence has evident conse-
quences for cellular therapy. In this paper we have dem-
onstrated that in human MSC cultured in  vitro under 
standard growth condition, the detection of prelamin 
A identifies senescent MSC. Since the onset of senes-
cence in a MSC culture is currently difficult to predict 
by the use of available markers, prelamin A staining 
could be successfully used to screen MSC populations 
before they are used for clinical applications alone or in 
combination with know and currently used senescence 
marker.
Fig. 3 Cell-cycle arrested cells are positive for prelamin A. Representative images of MSC immunostained for prelamin A (green), Ki67, and p21 
(both red in the panels). Cell nuclei were counterstained with DAPI (blue) and merged images are shown in the last column. Prelamin A positive cells 
(arrows) are negative for Ki67 and positive for p21. Scale bar 10 µm
Page 7 of 8Bellotti et al. SpringerPlus  (2016) 5:1427 
Abbreviations
SA-β-gal: senescence associated β-galactosidase; MSC: mesenchymal stem 
cells.
Authors’ contributions
CB designed and performed the experiments, analysed the data and wrote 
the manuscript. CC formulated the initial hypothesis, gave conceptual contri-
bution to the study, performed the experiments and revised the manuscript. 
GL provided financial support, gave conceptual contribution to the study 
and revised the manuscript. DD provided financial support and performed 
the harvest of bone-marrow samples. EL gave conceptual contribution to the 
study and revised the manuscript. SD designed and coordinated the study, 
performed the experiments, analysed the data and wrote the manuscript. All 
authors read and approved the final manuscript.
Author details
1 Osteoarticular Regeneration Laboratory, 3rd Orthopaedic and Traumatologic 
Clinic Prevalently Oncologic, Rizzoli Orthopaedic Institute, via di Barbiano 1/10, 
Bologna 40036, Italy. 2 Department of Biomedical and Neuromotor Sciences, 
University of Bologna, Bologna, Italy. 3 Institute of Molecular Genetics - Unit 
of Bologna, CNR-National Research Council of Italy, Bologna, Italy. 4 Laboratory 
of Musculoskeletal Cell Biology, Rizzoli Orthopaedic Institute, Bologna, Italy. 
Acknowledgements
The authors would like to thank the staff of the Third Orthopaedics and Trau-
matology Clinic (IOR, Bologna), for providing the cells used in this work, and 
Miss Lauren DeMaria BSc (Columbia University NY) for editorial assistance and 
English revision of the manuscript. The research was supported by Progetto 
FIRB-Accordi di programma 2010 (cod.RBAP10447J) of Italian Ministry of 
Education Universities and Research and by “5 per mille” 2011/2012 funding 
from Italian Ministry of Health.
Competing interests
The authors declare that they have no competing interests.
Research involving human participants
The study was reviewed and approved by the local Ethical Committee 
(Approval Record No. 21621). Patients signed an informed consent before the 
donation of bone marrow.
Received: 11 February 2016   Accepted: 17 August 2016
References
Banfi A, Muraglia A, Dozin B et al (2000) Proliferation kinetics and differentia-
tion potential of ex vivo expanded human bone marrow stromal cells: 
implications for their use in cell therapy. Exp Hematol 28:707–715
Broers J, Ramaekers F (2006) Nuclear lamins: laminopathies and their 
role in premature ageing. Physiol Rev 86:967–1008. doi:10.1152/
physrev.00047.2005
Caron M, Auclair M, Donadille B et al (2007) Human lipodystrophies linked 
to mutations in A-type lamins and to HIV protease inhibitor therapy are 
both associated with prelamin A accumulation, oxidative stress and pre-
mature cellular senescence. Cell Death Differ 14:1759–1767. doi:10.1038/
sj.cdd.4402197
Coppe J-P, Desprez P-Y, Krtolica A, Campisi J (2010) The senescence-associated 
secretory phenotype: the dark side of tumor suppression. Annu Rev 
Pathol 5:99–118. doi:10.1146/annurev-pathol-121808-102144
Crowe EP, Nacarelli T, Bitto A et al (2014) Detecting senescence: methods and 
approaches. In: Noguchi E, Gadaleta MC (eds) Cell cycle control. Springer, 
New York, NY, pp 425–445
Additional file
Additional file 1. Supplementary data.
Davies BS, Coffinier C, Yang SH et al (2011) Investigating the purpose of prel-
amin A processing. Nucleus 2:4–9. doi:10.4161/nucl.2.1.13723
de Girolamo L, Lucarelli E, Alessandri G et al (2013) Mesenchymal stem/stromal 
cells: a new cells as drugs’’ paradigm. Efficacy and critical aspects in cell 
therapy. Curr Pharm Des 19:2459–2473
de Jesus BB, Blasco MA (2012) Assessing cell and organ senescence biomark-
ers. Circ Res 111:97–109. doi:10.1161/CIRCRESAHA.111.247866
Debacq-Chainiaux F, Pascal T, Boilan E et al (2008) Screening of senescence-
associated genes with specific DNA array reveals the role of IGFBP-3 in 
premature senescence of human diploid fibroblasts. Free Radic Biol Med 
44:1817–1832. doi:10.1016/j.freeradbiomed.2008.02.001
Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O (2009) Proto-
cols to detect senescence-associated beta-galactosidase (SA-betagal) 
activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 
4:1798–1806. doi:10.1038/nprot.2009.191
Geißler S, Textor M, Kühnisch J et al (2012) Functional comparison of chrono-
logical and in vitro aging: differential role of the cytoskeleton and mito-
chondria in mesenchymal stromal cells. PLoS ONE 7:e52700. doi:10.1371/
journal.pone.0052700
Infante A, Gago A, de Eguino GR et al (2014) Prelamin A accumulation and 
stress conditions induce impaired Oct-1 activity and autophagy in pre-
maturely aged human mesenchymal stem cell. Aging (Albany NY) 1:1–17
Kim J, Choi YS, Lim S et al (2010) Comparative analysis of the secretory 
proteome of human adipose stromal vascular fraction cells during adipo-
genesis. Proteomics 10:394–405. doi:10.1002/pmic.200900218
Koch CM, Joussen S, Schellenberg A et al (2012) Monitoring of cellular senes-
cence by DNA-methylation at specific CpG sites. Aging Cell 11:366–369
Kong Y, Cui H, Ramkumar C, Zhang H (2011) Regulation of senescence in can-
cer and aging. J Aging Res 2011:963172. doi:10.4061/2011/963172
Kosar M, Bartkova J, Hubackova S et al (2011) Senescence-associated hetero-
chromatin foci are dispensable for cellular senescence, occur in a cell 
type- and insult-dependent manner and follow expression of p16ink4a. 
Cell Cycle 10:457–468. doi:10.4161/cc.10.3.14707
Lattanzi G, Ortolani M, Columbaro M et al (2014) Lamins are rapamycin 
targets that impact human longevity: a study in centenarians. J Cell Sci 
127:147–157. doi:10.1242/jcs.133983
Lee BY, Han JA, Im JS et al (2006) Senescence-associated 
β-galactosidase is lysosomal β-galactosidase. Aging Cell 5:187–195. 
doi:10.1111/j.1474-9726.2006.00199.x
Malashicheva A, Bogdanova M, Zabirnyk A et al (2015) Various lamin 
A/C mutations alter expression profile of mesenchymal stem cells 
in mutation specific manner. Mol Genet Metab. doi:10.1016/j.
ymgme.2015.04.006
Mattioli E, Columbaro M, Capanni C et al (2008) Drugs affecting prelamin 
A processing: effects on heterochromatin organization. Exp Cell Res 
314:453–462. doi:10.1016/j.yexcr.2007.11.012
Ragnauth CD, Warren DT, Liu Y et al (2010) Prelamin A acts to acceler-
ate smooth muscle cell senescence and is a novel biomarker of 
human vascular aging. Circulation 121:2200–2210. doi:10.1161/
CIRCULATIONAHA.109.902056
Righolt CH, Van’t Hoff MLR, Vermolen BJ et al (2011) Robust nuclear lamina-
based cell classification of aging and senescent cells. Aging (Albany NY) 
3(1192–1201):1004
Scaffidi P, Misteli T (2008) Lamin A-dependent misregulation of adult stem 
cells associated with accelerated ageing. Nat Cell Biol 10:452–459. 
doi:10.1038/ncb1708
Schellenberg A, Lin Q, Schüler H et al (2011) Replicative senescence of mesen-
chymal stem cells causes DNA-methylation changes which correlate with 
repressive histone marks. Aging (Albany NY) 3:873–888
Sepúlveda JC, Tomé M, Fernández ME et al (2014) Cell senescence abrogates 
the therapeutic potential of human mesenchymal stem cells in the lethal 
endotoxemia model. Stem Cells. doi:10.1002/stem.1654
Shay JW, Wright WE (2000) Hayflick, his limit, and cellular ageing. Nat Rev Mol 
Cell Biol 1:72–76. doi:10.1038/35036093
Sherley JL (2002) Asymmetric cell kinetics genes: the key to expansion 
of adult stem cells in culture. Stem Cells 20:561–572. doi:10.1634/
stemcells.20-6-561
Shibata KR, Aoyama T, Shima Y et al (2007) Expression of the p16INK4A gene 
is associated closely with senescence of human mesenchymal stem cells 
and is potentially silenced by DNA methylation during in vitro expansion. 
Stem Cells 25:2371–2382. doi:10.1634/stemcells.2007-0225
Page 8 of 8Bellotti et al. SpringerPlus  (2016) 5:1427 
Stenderup K, Justesen J, Clausen C, Kassem M (2003) Aging is associated with 
decreased maximal life span and accelerated senescence of bone mar-
row stromal cells. Bone 33:919–926. doi:10.1016/j.bone.2003.07.005
Vlcek S, Foisner R (2007) Lamins and lamin-associated proteins in aging and 
disease. Curr Opin Cell Biol 19:298–304. doi:10.1016/j.ceb.2007.04.001
Wagner W, Horn P, Castoldi M et al (2008) Replicative senescence of mes-
enchymal stem cells: a continuous and organized process. PLoS ONE 
3:e2213. doi:10.1371/journal.pone.0002213
Wagner W, Bork S, Horn P et al (2009) Aging and replicative senescence have 
related effects on human stem and progenitor cells. PLoS ONE 4:e5846
Whitfield MJ, Lee WCJ, Van Vliet KJ (2013) Onset of heterogeneity in culture-
expanded bone marrow stromal cells. Stem Cell Res 11:1365–1377. 
doi:10.1016/j.scr.2013.09.004
Wuchter P, Bieback K, Schrezenmeier H et al (2014) Standardization of Good 
Manufacturing Practice-compliant production of bone marrow-derived 
human mesenchymal stromal cells for immunotherapeutic applications. 
Cytotherapy 17:128–139. doi:10.1016/j.jcyt.2014.04.002
Yang NC, Hu ML (2005) The limitations and validities of senescence 
associated-β- galactosidase activity as an aging marker for human 
foreskin fibroblast Hs68 cells. Exp Gerontol 40:813–819. doi:10.1016/j.
exger.2005.07.011
Yoo JK, Choi S-J, Kim JK (2013) Expression profiles of subtracted mRNAs during 
cellular senescence in human mesenchymal stem cells derived from 
bone marrow. Exp Gerontol. doi:10.1016/j.exger.2013.02.022
Yu K-R, Kang K-S (2013) Aging-related genes in mesenchymal stem cells: a 
mini-review. Gerontology. doi:10.1159/000353857
Yu KR, Lee S, Jung JW et al (2013) MicroRNA-141-3p plays a role in human 
mesenchymal stem cell aging by directly targeting ZMPSTE24. J Cell Sci 
126:5422–5431. doi:10.1242/jcs.133314
